Remove Disease Remove Imaging Remove Pharmaceutical
article thumbnail

Hormone therapy linked to tau accumulation in older women

AuntMinnie

A PET study has revealed that women over the age of 70 who took menopausal hormone therapy (HT) more than a decade before have faster brain tau accumulation -- a key indicator of Alzheimers disease. The findings may inform [Alzheimers disease] risk discussions relating to womens reproductive health and treatment, the group wrote.

Disease 162
article thumbnail

Radiotracer for kidney cancer performs well in phase III trial

AuntMinnie

The imaging agent fills an unmet need to identify small lesions, which could allow earlier diagnosis of the disease, noted lead author Brian Shuch, MD, of the University of California, Los Angeles, and colleagues. Images available under Creative Commons license (CC BY 4.0 Images available under Creative Commons license (CC BY 4.0

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Brainomix, Boehringer Ingelheim partner on improving lung disease care

AuntMinnie

AI imaging firm Brainomix has entered into a partnership with German pharmaceutical company Boehringer Ingelheim to improve the care of U.S. patients with fibrosing lung disease. Through the partnership, Brainomix will deploy its e-Lung software, which has 510(k) clearance from the U.S.

Disease 100
article thumbnail

Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

Imaging Technology

announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4, on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status amyloid plaque in the brain.

Disease 105
article thumbnail

Telix inks distribution deal for Zircaix

AuntMinnie

Telix Pharmaceuticals has selected Cardinal Health to distribute its PET agent TLX250-CDx (Zircaix) for imaging kidney cancer in the U.S., In a recent phase III trial , the radiotracer was shown to be safe and effective for identifying small lesions, which could allow for earlier diagnosis of the disease. the company noted.

article thumbnail

Enigma Biomedical inks deal to develop tau PET biomarkers

AuntMinnie

Enigma Biomedical Group USA (EBG-USA) has signed an exclusive agreement to commercialize AbbVie’s tau PET imaging biomarkers for use in patients with suspected neurodegenerative disease. Tau ligands labeled with F-18 radioisotopes are used as radiotracers during PET imaging to visualize this pathology.

article thumbnail

FDA fast-tracks Clarity’s prostate cancer treatment

AuntMinnie

Clarity Pharmaceuticals has secured fast-track designation from the U.S. The classification builds on Clarity's earlier receipt of fast-track designation for its PET diagnostic imaging agent Cu-64 SAR-bisPSMA for identifying patients with the disease.